Core Insights - Ocular Therapeutix has launched a new corporate branding and website, marking a significant transformation towards becoming a retina-focused company [1][8] - The new branding reflects the company's innovative vision and commitment to redefining the retina experience, particularly in the treatment of retinal diseases [3][6] Company Overview - Ocular Therapeutix, Inc. is a biopharmaceutical company dedicated to redefining the retina experience, with a focus on innovative treatments for retinal diseases [9] - The investigational therapy AXPAXLI™ (OTX-TKI) is an axitinib hydrogel designed for intravitreal injection, aimed at improving treatment durability and long-term outcomes for patients with wet age-related macular degeneration (wet AMD) [7][9] Market Context - Wet AMD affects approximately 1.8 million people in the U.S., and current treatment options often require up to 12 injections per year, leading to patient burden and potential treatment discontinuation [6] - The company aims to disrupt existing treatment paradigms for retinal diseases, addressing the high burden associated with current pulsatile treatments [6][3] Product Pipeline - Ocular's pipeline includes AXPAXLI™, currently in Phase 3 clinical trials for wet AMD, and DEXTENZA, an FDA-approved corticosteroid for ocular inflammation and pain [10] - The investigational product OTX-TIC is in Phase 2 clinical trials for open-angle glaucoma or ocular hypertension, leveraging the company's proprietary ELUTYX™ technology [10]

SOL-1, Ocular's first registrational trial in wet AMD, completed randomization in December 2024 and retention remains exceptional as the trial continues on track for top-line readout in 1Q 2026 These two complementary trials are intended to form the basis of an NDA submission of AXPAXLI in wet AMD BEDFORD, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular"), a fully-integrated biopharmaceutical company committed to redefining the retina experience, today announced that ...

Core Viewpoint - Ocular Therapeutix, Inc. is actively participating in several investor and scientific conferences in May 2025 to showcase its advancements in retinal therapies and engage with the investment community [1][2][3]. Upcoming Investor Conferences - Ocular Therapeutix will present at the Citizens JMP Life Sciences Conference on May 7, 2025, at 9:00 AM ET in New York, NY, with CEO Pravin U. Dugel as the presenter [2]. - The company will also participate in the Bank of America 2025 Global Healthcare Conference on May 13, 2025, at 9:20 AM PT in Las Vegas, NV, again featuring CEO Pravin U. Dugel [2]. Upcoming Scientific Conferences - At the Eyecelerator @ Park City 2025, Ocular will have a panel titled "Retina in Office" on May 2, 2025, focusing on novel drug delivery approaches for glaucoma and retina, with Chief Medical Officer Nadia K. Waheed as a panelist [3]. - Ocular will present at the Association for Research in Vision and Ophthalmology (ARVO) 2025 on May 6, 2025, discussing the HELIOS trial for diabetic retinopathy, with Neal Shah, MD, as the presenter [4]. - The company will also showcase various posters at ARVO 2025, including studies on axitinib hydrogel injections and their effects on diabetic retinopathy [5][6]. Company Presentation Highlights - Ocular Therapeutix will present on "Retina - TKI and Drug Delivery Showcase" on May 2, 2025, with Chief Strategy Officer Sanjay Nayak as the presenter [4]. - The company will also participate in the Retina World Congress (RWC) 2025, presenting updates on clinical trials related to axitinib intravitreal hydrogel and diabetic retinopathy on May 9 and 10, 2025 [7][8]. Company Overview - Ocular Therapeutix is a biopharmaceutical company focused on retinal disease therapies, with its investigational product AXPAXLI (axitinib intravitreal hydrogel) currently in Phase 3 clinical trials for wet age-related macular degeneration [9]. - The company also leverages its proprietary ELUTYX technology in its commercial product DEXTENZA, an FDA-approved treatment for ocular inflammation and pain [10].

Core Viewpoint - Ocular Therapeutix, Inc. plans to release its first quarter 2025 financial results on May 5, 2025, at 7:00 AM Eastern Time, and will not hold a conference call for this quarter, resuming calls for the second quarter 2025 [1]. Company Overview - Ocular Therapeutix, Inc. is a biopharmaceutical company focused on redefining the retina experience [3]. - The company’s investigational product AXPAXLI™ (axitinib intravitreal hydrogel, also known as OTX-TKI) is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD) [3]. - Ocular's pipeline includes DEXTENZA, an FDA-approved corticosteroid for treating ocular inflammation and pain post-surgery, and PAXTRAVA™ (travoprost intracameral injection or OTX-TIC), which is in Phase 2 clinical trials for open-angle glaucoma or ocular hypertension [4].